Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce side effects and injection fatigue by providing steady drug release under the skin. While promising, the device is still in early clinical trial stages and must overcome regulatory and adoption challenges before reaching patients. If successful, it could offer a convenient maintenance option to sustain weight loss and reduce healthcare costs associated with obesity-related conditions.
Deutsche Bank downgraded Novo Nordisk shares from 'hold' to 'sell', cutting the target price by 9% due to concerns over midterm growth and pipeline setbacks. The downgrade follows a mixed Q2 update and highlights worries about limited Medicare prescr...
In Q2 2026, Eli Lilly reported a strong 48% revenue growth driven by blockbuster obesity drugs Mounjaro and Zepbound, especially with rapid international expansion. Novo Nordisk faced challenges including shrinking U.S. sales, price cuts, layoffs, an...
Eli Lilly has introduced Foundayo, an oral GLP-1 pill for weight loss and type 2 diabetes, in UK pharmacies following recent approval. This tablet offers a convenient alternative to injections and is licensed for adults with certain BMI criteria or w...
Novo Nordisk's stock appears to have formed a long-term bottom as its turnaround gains momentum, with losses in market share to Eli Lilly stabilizing. Trading at just over 15 times forward earnings, the stock is valued at about half of Eli Lilly's mu...
